secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001104659-24-089295
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q2 net loss narrows to $2.5M; FDA alignment on NurOwn Phase 3b trial CMC
--------------------------------------------------------------------------------

- Net loss for Q2 2024 was $2.5M ($0.04/sh), compared to $5.3M ($0.13/sh) in Q2 2023.
- Cash, cash equivalents, and restricted cash were $3.65M as of June 30, 2024.
- Reached FDA alignment on CMC aspects for Phase 3b NurOwn trial in ALS, following SPA agreement in April.
- Appointed Hartoun Hartounian Ph.D. as EVP/COO and promoted Dr. Bob Dagher to EVP/CMO.
- Completed registered direct offering raising $4.0M gross proceeds from single institutional investor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924089295/0001104659-24-089295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924089295/tm2421455d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer